Sanguine expands services into the clinical space
Sanguine, a Los Angeles, Calif.-based technology company providing services to the personalized medicine and biomedical research market, is expanding its services to improve clinical trial efficiency through enhanced patient recruitment, retention and trial procedures. Sanguine, which primarily operated in the preclinical space until now, will be fulfilling needs in later stage clinical development through a combination of smart technology and adaptable mobile health force.
“Currently, the clinical trial process is slow and inefficient. Trials take 30%-40% longer than expected due to poor recruitment, 15%-40% of patients drop out before they finish and trial procedures are becoming increasingly complex,” said Brian Neman, CEO and co-founder of Sanguine. “There is a huge need in the market to solve these issues and make the clinical trial process faster and more robust. At Sanguine, we are committed to advancing biomedical research by providing a comprehensive solution that spans the entire clinical development process.”
Sanguine offers a personalized approach to patient visits and sample collection. Through the Sangre Dashboard, a portal used to track patient progress and submit requests for at home visits, sites can better monitor activities and appointments. After a patient schedules an appointment through the Sangre Dashboard, a local phlebotomist or nurse from Sanguine’s protocol-trained Mobile Health Force is alerted on Sangre, Sanguine’s proprietary mobile application, and dispatched to the patient’s home to perform trial procedures.
After samples and data are processed and submitted, the site is notified of completion via the Sangre Dashboard. Sanguine’s Mobile Health Force spans across 42 cities in the U.S., Canada, Italy and the U.K. The combination of Sanguine’s unique technology and global team of health professionals results in wider patient access, improved retention and compliance rates, an earlier last site last visit (LSLV) as well as reduced per site and per patient cost.
“By expanding our focus to include the clinical space, we will have the opportunity to work with a much larger research population and make a greater impact on medical research,” said Carlyn Crisostomo, chief operating officer of Sanguine. “Our goal is to create a more efficient clinical trial process for both researchers and patients by leveraging technologies like our Sangre Dashboard and Sangre Mobile Application.”
With over 200 unique protocols completed and partnerships with top pharmas, Sanguine is committed to creating the next generation of treatment and diagnostics for a multitude of diseases. Sanguine is currently working on studies with an emphasis on autoimmune and rare conditions.